Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 5211SC

5211SC 10 µg (With Carrier)
5211SF 10 µg (Carrier Free)
5211LC 50 µg (With Carrier)
5211LF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant mouse VEGF164 (mVEGF164) Ala205-Arg368 (Accession #NP_033531) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mVEGF164. All lots are greater than 98% pure.


Molecular Formula:

Recombinant mVEGF164 contains no "tags" and the nonglycosylated protein has a calculated MW of 19,278. DTT-reduced protein migrates as a 24-31 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 38-44 kDa protein. The expected amino-terminal APTTE of recombinant mVEGF164 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant mVEGF164 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-5 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg mVEGF164.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mVEGF164. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

VEGF164 is one of many splice variants of the mouse VEGF-A gene, and is one amino acid shorter than its human counterpart, VEGF165 (1,2). VEGF164 is produced by a number of cells including endothelial cells, macrophages and T cells (1,2). VEGF164 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1,2). Gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF164 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (1-3). VEGFR1 and VEGFR2 are the receptor tyrosine kinases for VEGF164 (2). NRP-1 and NRP-2 may function as co-receptors and enhance VEGFR2 signaling (2-3). Binding of VEGF164 to VEGFR1 and VEGR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and Paxillin (2).


1.  Haigh, J.J. (2008) Organogenesis 4, 247-56.

2.  Takahashi, H. and Shibuya, M. (2005) Clin Sci (Lond) 109, 227-41.

3.  Neufeld, G. et al. (1999) FASEB J 13, 9-22.


Entrez-Gene Id 22339
Swiss-Prot Acc. Q00731


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.